<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 10, 2000
LJL BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
000-23647
(Commission File Number)
DELAWARE 77-0360183
(State or other jurisdiction of (I.R.S. Employer
incorporation) Identification No.)
405 TASMAN DRIVE
SUNNYVALE, CA 94089
(Address of principal executive offices, with zip code)
(408) 541-8787
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
On April 20, 2000, LJL BioSystems, Inc. announced that it has been awarded
a Phase 1 Small Business Innovation Research (SBIR) grant from the National
Institutes of Health. The grant is for research into the application of LJL's
High Efficiency Fluorescence Polarization (HEFP(TM)) technology for measuring
G-protein coupled receptor (GPCR) signaling. Further details regarding this
announcement are contained in the company's news release dated April 20, 2000
attached as an exhibit hereto and incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Exhibits:
99.16 LJL BioSystems, Inc. News Release dated April 20, 2000
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LJL BIOSYSTEMS, INC.
Date: April 20, 2000 By: /s/ Lev J. Leytes
------------------------
Lev J. Leytes
President and CEO
-3-
<PAGE>
Exhibit 99.16
FOR IMMEDIATE RELEASE
LJL BIOSYSTEMS AWARDED SBIR GRANT TO FURTHER RESEARCH GPCR SIGNALING USING
LJL'S HEFP TECHNOLOGY
SUNNYVALE, Calif.--(BW HealthWire)--April 20, 2000--LJL BioSystems, Inc.
(Nasdaq:LJLB) today announced that it has been awarded a Phase 1 Small Business
Innovation Research (SBIR) grant from the National Institutes of Health. The
grant is for research into the application of LJL's High Efficiency Fluorescence
Polarization (HEFP(TM)) technology for measuring G-protein coupled receptor
(GPCR) signaling. GPCRs are critical to many physiological processes and many of
the drugs today interact with GPCR targets. Due to the human genome sequencing
efforts, significantly more new GPCRs are being discovered.
"We are excited about our first SBIR grant because it serves to supplement our
ongoing development of a portfolio of HEFP assays directed at the analysis of
GPCRs. We believe the National Institutes of Health's awarding of this
competitive SBIR grant is further evidence of the growing recognition of LJL's
scientific leadership," commented Lev J. Leytes, Chairman and CEO of LJL.
About LJL BioSystems, Inc.
LJL BioSystems designs, produces and sells infrastructure tools that accelerate
and enhance the process of discovering new drugs in the genomics and
post-genomics era. Our products, including instruments and consumables, are
designed to provide flexible, cost-efficient, high throughput solutions that can
be used across all stages of the drug discovery process, including screening and
genotyping. Our worldwide customers include pharmaceutical, biotechnology and
genomics companies as well as research institutions. LJL's customers include,
among others, AstraZeneca, Aventis, Bristol Myers Squibb, SmithKline Beecham,
Eli Lilly, Pfizer, Merck, Johnson and Johnson, Tularik, Millennium
Pharmaceuticals, Amgen, and Incyte. LJL is headquartered in Sunnyvale,
California and has a subsidiary in the United Kingdom. Additional information
can be found at www.ljlbio.com.
Forward-Looking Statements
Statements made in this news release, other than statements of historical fact,
are forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act, including statements regarding LJL's "expectations,"
"goals," "beliefs," "hopes," "designs," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially, including such factors, among others, as the
impact of competitive products and pricing, the timely development and market
acceptance of new products, the ability to raise capital, concentration of HTS
and Ultra-HTS markets, market conditions, the mix between domestic and
international sales, manufacturing and cost of LJL's products, dependence on
collaborative partners, the enforcement of intellectual property rights,
-4-
<PAGE>
and uncertainties relating to sole source suppliers, technological approaches,
FDA and other regulatory approvals. These and other risk factors are discussed
in LJL's Annual Report on Form 10-K, filed February 16, 2000, and its
Registration Statement on Form S-3 filed on March 14, 2000 (see, in particular,
Risk Factors and Management's Discussion and Analysis of Financial Condition and
Results of Operations). LJL disclaims any intent or obligation to update these
forward-looking statements. As a result of these and other factors, LJL expects
to experience significant fluctuations in operating results, and there can be no
assurance that LJL will become or remain consistently profitable in the future.
For information on LJL BioSystems, Inc., contact Larry Tannenbaum, Chief
Financial Officer, at 408-548-0542 or [email protected].
CONTACT: LJL BioSystems, Inc.
Larry Tannenbaum, 408/548-0542
[email protected]
or
Friestedt International
Susanne Friestedt, 619/223-8844 (Media)
[email protected]
-5-
